Metabolic pathways involving uric acid and homocysteine may play a role in the onset of peripheral neuropathy in patients with Parkinson’s disease, a study suggests. The study, “Peripheral Neuropathy in de novo Patients with Parkinson’s Disease,” was published in the Yonsei Medical Journal. Peripheral…
A poor performance, due to cognitive impairments, on the Rookwood Driving Battery (RDB) — a set of tests aiming to evaluate specific neuropsychological skills that are important for safe vehicle operation — is the best predictor of poor driving among patients with Parkinson’s disease, a study has found.
MapLight Therapeutics will use an $8.1 million three-year grant to tackle the common symptoms of anxiety and depression in Parkinson’s disease. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) grant will enable the biopharmaceutical company to open an expansive, systematic exploration of brain circuits and…
An upcoming clinical trial, known as the AZA-PD study, will test whether limiting the activity of the immune system through the use of an immunosuppressant can slow the progression of Parkinson’s disease. The Phase 2 trial (ISRCTN14616801) — officially Azathioprine immunosuppression and disease modification in Parkinson’s disease…
Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease. “The signing of this clinical study agreement represents a significant milestone for the Company as we…
The Parkinson’s Personal KinetiGraph (PKG), a small motion sensor device that can be worn on the wrist like a watch in patients with Parkinson’s disease, can be used to detect abnormal movements, especially those associated with bradykinesia at the earlier stages of the disorder, an observational…
Eisai is partnering with Wren Therapeutics to advance the discovery of new small molecule compounds capable of reducing the misfolding and aggregation of alpha-synuclein, the underlying cause of different neurological disorders, including Parkinson’s disease and dementia with Lewy bodies. The research collaboration will leverage Wren’s…
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Nuplazid (pimavanserin) that will allow the medication to be taken more easily by Parkinson’s patients who have difficulty swallowing. Nuplazid, by Acadia Pharmaceutical, is an oral medication that was approved…
AbFero Ltd will receive approximately €2 million ($2.41 million) through Eureka Network’s Eurostars program to complete pre-clinical testing of SP-420, a potential disease-modifying therapy for Parkinson’s disease, and to develop other iron-removing compounds. “This grant is an important step forward for AbFero as we test…
Xeomin (incobotulinumtoxinA) has been approved by Health Canada to treat adults with chronic sialorrhea — excessive drooling — a condition often experienced by people with neurological conditions like Parkinson’s disease. “The reality is that uncontrolled salivation is underestimated in many neurological diseases,” Michel…
Get regular updates to your inbox.
